Save The Date: November 1-2, 2017
10 on the Park, New York City

Emerging Company Showcase

Innovative, Fundable, Early Stage Opportunities

Each company featured in the Emerging Company Showcase was nominated, reviewed and invited to present based upon their innovative science and the quality of their management team. They presented before a panel of ‘Pitch Doctors’, early stage VCs and investors, corporate VCs, strategic partners and other investors and advisors, who asked questions about their science and strategy. View the 2016 showcase presenters here. 

2017 Presenting Companies

2xonco

2X Oncology, Inc., Cambridge, MA: Developing precision medicine CDx technology using systems biology analytics, big-data algorithm and transcriptomic expression profiling for cancer treatment.

 afasci

Afasci, Redwood city, CA: Developing targeted therapies for treatment of neuropathic pain. (NINDS)

agile Agile Sciences, Raleigh, NC: Developing novel 2-aminoimidazole (2-AI) compounds to enhance antimicrobial efficacy for the treatment of antibiotic resistant, life-threatening infections.
allvivo2 Allvivo Vascular, Lake Forest, CA: Developing antimicrobial and biocompatible coatings for medical devices and combination products. (NHLBI)
aqumin Aqumin, LLC, Houston, TX: Developed 3D software system for large clinical trial data analysis.

arteriummedical

Arterium Medical LLC, Princeton, NJ: Developing non-invasive disposable sensor technology implements to be used to transdermally monitor peripheral arterial blood flow continuously to aide in the early identification of life-threatening circulatory collapse that requires urgent intervention such as in sepsis, cardiac shock or internal bleeding. (NHLBI)
bbn BBN Cardio Therapeutics, New York, NY: Developing Pa/HDa-216, an orally administered drug produced from algae to treat the plaques that contribute to atherosclerosis.
bioharmony Bioharmony Therapeutics, New York, NY: Developing antimicrobial therapeutics targeting infectious diseases caused by multidrug-resistant (MDR) Gram-negative bacteria, especially nosocomial infections.
barc Biomedical Acoustics Research Company, Orlando, FL: Developing technologies for diagnosis (and possibly for therapeutics) utilizing sound in the acoustic range. (NHLBI)
blinkbio BlinkBio, Jupiter, FL: Developing Bioorthogonal Linker (“BLink”) chemistries through Tunable Drug Conjugates (TDCs) platform for the treatment of oncology and other diseases.
caelum Caelum Biosciences, New York, NY: Developing treatments for rare and life-threatening conditions including CAEL-101, a novel antibody for patients with AL Amyloidosis.
cancurellc CanCure LLC, Charleston, SC: Developing immunotherapeutic antibody, CuraB-10, for cancer treatment. (NCI)
cardea Cardea Sciences, New York, NY: Developing platform technology to risk stratify cardiac patients based on their hemodynamic state.
carmell Carmell Therapeutics, Pittsburgh, PA: Developing innovative Plasma-based Bioactive Materials (PBMs) which can be applied across orthopedics, soft tissue healing, burn, dermatology and other aspects of medicine.
certerra Certerra Inc., Cold Spring Harbor, NY: Developing PharmacomapTM method of screening neural activation across the entire brain applicable for screening of novel compounds being developed for a broad spectrum of brain disorders, including neurodevelopmental, psychiatric and neurodegenerative ones, as well as repurposing of existing drugs.
codagenix1 Codagenix, Farmingdale, NY: Developing SAVE (Synthetic Attenuated Virus Engineering), a software-based platform to construct live-attenuated viral vaccines against multiple targets.
concarlo Concarlo Holdings, LLC, Brooklyn, NY: Developing a biomarker assay to be used to pinpoint patients that would respond to cdk4-inhibiting therapies for the treatment of breast cancer.
cyclica Cyclica, Toronto, Canada: Developing a cloud-based platform that screens small-molecule drugs against repositories of structurally-characterized proteins or ‘proteomes’ to determine polypharmacological profiles
 cytocybernetics Cytocybernetics, North Tonawanda, NY: Developing a proprietary drug safety screening assay based on a unique computer-cell interface, the Cybercyte, which allows more accurate and rapid determination of the pro-arrhythmic properties of a compound using stem-cell derived cardiac myocytes.(NHLBI)
denton Deton, Pasadena, CA: Developing the non-invasive Cough Collector platform which enables the capture, isolation, and analysis of a biological sample originating in the lungs and expelled as an aerosol through cough for the management of lung health. (NHLBI)
 dignify Dignify Therapeutics LLC, Durham, NC: Developing developing treatments (drugs and devices) for voiding dysfunction (bladder and bowel) associated with spinal cord injury, diabetes, aging, etc. (NINDS)
enbtherapeutics ENB Therapeutics, New York, NY: Developing small molecule inhibitors of a novel pathway to treat melanoma and other cancers.
epidestiny EpiDestiny Inc., Cleveland, OH: Developing EPI01. a non-toxic, Gene Control Therapy to improve hemoglobin in Sickle Cell Disease. (NHLBI)
fesarius FesariusTherapeutics Inc., New York, NY: Developing and manufacturing engineered skin replacement products using patented microsphere hydrogel technology. Presenter: Brett Spector, PhD, Co-Founder and CEO
glycomantra GlycoMantra, Aldie, VA: Developing natural high affinity galectin-3 inhibitors (for the treatment of cancer and fibrotic diseases. (NCI)
 hemogenyx HemoGenyx LLC, Brooklyn, NY: Developing novel therapies and treatments for blood diseases, like leukemia and lymphoma.
hillhurst Hillhurst Biopharmaceuticals, Inc., Montrose, CA: Developing therapeutics targeting the cytoprotective heme oxygenase pathway for use in sickle cell disease, kidney transplant, and TBI, among other inflammatory conditions. (NHLBI)
icell_web iCell Gene Therapeutics, Stony Brook, NY: developing Chimeric Antigen Receptor (CAR) engineered cells that target multiple types of cancer with very poor prognoses and clear unmet medical need.
icellvivo iCellVivo, Irvine, CA: Organ systems platform for drug development. (NHLBI) 
 jaanbio Jaan Biotherapeutics, San Diego, CA: preclinical stage biotechnology company developing a regenerative therapy that modulates the activity of microRNAs to repair damaged heart muscle to treat Ischemic Heart Disease. (NHLBI)
mangogen MangoGen Pharma, Quebec, Canada: Developing gene-delivering cardiac stents and wound healing creams using modified baculoviruses.
 navigen Navigen, Salt Lake City, UT: Leveraging the unique properties of D-peptides developing a new class of therapies targeting areas of unmet needs including treatment and prevention of HIV and respiratory syncytial virus (RSV). (NHLBI)
nmtlogo2 NeoMatrix Therapeutics, Inc., Stony Brook, NY: Developing novel therapeutic agents for the treatment of serious burn injuries.
neuroparticle2 Neuroparticle Corporation, Rockville, MD: MRI-guided non-invasive method of treating addiction and other neurological conditions. (NINDS)
phoenixnest Phoenix Nest, Brooklyn, NY: Developing treatments for Sanfilippo Syndrome IIIC and IIID, using approaches that include enzyme replacement and chaperone therapies. (NINDS)
privo Privo Technologies, Peabody, MA: Developing a novel, nanotechnology-based drug delivery platform capable of local and systemic delivery of a constant, controlled therapeutic dose through the mucosa. (NCI)
 prothera Prothera Biologics, Providence, RI: developing Inter-Alpha Inhibitor Proteins (IAIP) to treat severe inflammation associated with infection, trauma and disease. (NINDS)
  SaNOtize, North Vancouver BC: Developing a platform technology that enables prevention/treatment of normal and drug resistant microbial infections.
  SelectION, San Diego, CA: Developing highly selective peptide blockers for ion channels for the treatment of autoimmune diseases.
sfa SFA therapeutics, Jenkintown, PA: Developing treatments targeting NF-Kb to address chronic inflammatory diseases.
shifabiomed Shifa Biomedical Corporation, Malvern, PA: Utilizing advanced computational methods coupled with innovative biological assays to discover novel oral small-molecule antagonist for the treatment of dyslipidemia. (NHLBI)
soundpipe SoundPipe, LLC, Charlottesville, VA: Developing an intravascular ultrasound system using a catheter mounted ultrasound device to image the vessel and improve drug delivery for the treatment of Critical Limb Ischemia (CLI). (NHLBI)
stemmed StemMed, Houston, TX: Developing C188-9, an oral inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3), for targeted therapy of breast cancer (including triple-negative), and other diseases. (NCI)
sns Sustained Nano Systems, Stony Brook, NY: Developing patented nanotechnology that extends the time release of a wide range of biologically active molecules in a predictable manner, from weeks to months.
synvivo Synvivo, Huntsville, AL: Developing microfluidic chips capable of supporting a microvascular network that simulates the circulation inside any tissue with respect to flow, shear and pressure. (NCI)
targagenix_web TargaGenix, Stony Brook, NY: Developing novel compounds that are effective on both drug-resistant tumors and cancer stem cells.
teamedon_gen1 TeamedOn International, Gaithersburg, MD: Developing novel small molecule therapeutics targeting Acute Myeloid Leukemia (AML).
thirdpole Third Pole, Inc, San Francisco, CA: Developing a tankless electric Nitric Oxide for hospital, ambulatory and home use. (NHLBI)
vanguard Vanguard Therapeutics, Inc., Half Moon Bay, CA: Developing an oral P-selectin blocker for the treatment of sickle cell disease. (NHLBI)
vascugen Vascugen, Inc., Indianapolis, IN – Advancing a pipeline of regenerative medicines for treatment of intractable vascular diseases.
vesselon Vesselon, Norwalk, CT: Developing a drug delivery platform that combines ultrasound and microbubbles to noninvasively enhance the delivery of drugs more effectively across tissue barriers.

*Select companies are participating with the support the National Institutes of Health – the specific supporting institute, National Cancer Institute (NCI), National Heart Lung Blood Institute (NHLBI) or National Institute for Neurological Disorders and Stroke (NINDS) is noted at the end of the company description.

2017 Participating Strategic Partners and Investors:

Accelerate NY Seed Fund
Accelerator Corporation
Aisling Capital LLC
Ajax Ventures
Ajes Life Sciences
Alexandria LaunchLabs
Allergan
ARCH Venture Partners
ARD Healthcare
AstraZeneca
Barer & Son Capital
BioAdvance
BioMotiv
BioVantage Investments
Bruder Consulting and Venture Group
Caladrius Biosciences
Cancer Research Institute
Canon BioMedical
Celdara Medical
Charles River Ventures
Chai Tai Tianqing Pharmaceutical Group Co. LTD
COI Pharmaceuticals, Inc
Courage Growth Partners
CQDM
CTI Life Sciences
Deerfield
Elanco 
Eli Lilly and Company
Enso Ventures
Faridan
Fortress Biotech
FoxHill Asset Management
FundRx
Golden Seeds
H.I.G. Capital
Hatteras Venture Partners
Hengrui Medicine
InCube Ventures
Johnson & Johnson 
KdT Ventures
Landmark Angels, Inc.
LIFE Fund
Long Island Angel Network
MedCare One LLC
MedImmune
Merck
Mid Atlantic Bio Angels
Mount One Capital
MP Healthcare Venture Management Inc.
New Ventures Funds
New York Ventures
NJ Angels + Investors Life Sciences Networks
OCT
OrbiMed
Pappas Ventures
Pfizer
Remiges Ventures
Roche
Roivant Sciences, Inc.
SynMA Capital LLC
The Michael J. Fox Foundation for Parkinson’s Research
TRI – MEDIX, LLC
Trillium Medical Ventures
Two Sigma Ventures
U.S. Trust, Bank of America Private Wealth Management
Varana Capital, LLC
Venrock Healthcare